The 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) was held in Chicago, IL from June 1–5, 2018. In accordance with the ASCO meetings over the past few years, immuno-oncology therapies took center-stage with new data presented on more mature drug classes, such as PD-1/PD-L1 inhibitors and CAR-T therapies, as well as up-and-coming mechanisms, such as ICOS-targeted drugs and CD-122-biased cytokines.
This post-meeting report features summaries of a few key topics along with commentary from our anal.on specific presentations. It also includes a compilation of all data events added in conjunction with the meeting.
This post-meeting report features summaries of a few key topics along with commentary from our anal.on specific presentations. It also includes a compilation of all data events added in conjunction with the meeting.
Table of Contents
Meeting Overview – Key IndicationsNon-small cell lung cancer (NSCLC)
Renal cell cancer (RCC)
Breast cancer
Multiple myeloma
Chronic lymphocytic leukemia (CLL)
Waldenström's macroglobulinemia (WM)
Hairy cell leukemia (HCL)
Follicular lymphoma (FL)
Diffuse large B cell lymphoma (DLBCL)
Meeting Overview – Key Companies
Loxo Oncology (LOXO)
Nektar Therapeutics (NKTR)
Forty Seven Inc. (FTSV)
bluebird bio (BLUE)
Key Drug Analyses and Abstracts
Acute Lymphocytic Leukemia (ALL)
Yescarta (GILD, Phase I/II)
Acute Myelogenous Leukemia (AML)
Bemcentinib (BerGenBio, Development Outside U.S.)
FT-2102 (FORMA Therapeutics, Phase I/II)
Bladder Cancer
Enfortumab Vedotin (Astellas, Phase II)
Cabometyx / Cometriq (EXEL, Phase II)
JNJ-42756493 (JNJ, Phase II)
Brain Cancer (Secondary; Metastases)
Tafinlar (NVS, Phase II)
Breast Cancer
AZD5363 (AZN, Phase I/II)
Imfinzi (AZN, Phase II)
DS-8201 (Daiichi Sankyo, Phase II)
G1T38 (GTHX, Phase I/II)
Sacituzumab Govitecan (IMMU, BLA)
Talazoparib (PFE, NDA)
Taselisib (Roche, Suspended)
Zejula (TSRO, Phase III)
ZW25 (ZYME, Phase I)
Cancer
CX-072 (CTMX, Phase I/II)
Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL
Imbruvica (ABBV, Approved)
Diffuse Large B-Cell Lymphoma (DLBCL) - NHL
Lisocabtagene Maraleucel (CELG, Phase I/II)
Yescarta (GILD, Approved)
Polatuzumab (Roche, Phase III)
Esophageal Cancer
Keytruda (MRK, Phase III)
Gastric Cancer
Keytruda (MRK, Approved)
Napabucasin (Sumitomo Dainippon, Suspended)
Hairy Cell Leukemia
Moxetumomab Pasudotox (AZN, BLA)
Hematologic Cancer
ME-401 (MEIP, Phase I)
Cerdulatinib (PTLA, Phase I/II)
Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases)
Lenvima (ESALY, NDA)
ADI-PEG 20 (Polaris Group, Phase III)
Tecentriq (Roche, Phase III)
Indolent Non-Hodgkin's Lymphoma (Including Follicular Lymphoma) - NHL
Revlimid (CELG, Phase III)
Polatuzumab (Roche, Phase II)
Melanoma
Epacadostat (INCY, Suspended)
Indoximod (NLNK, Phase II/III)
Multiple Myeloma (MM)
Venclexta (ABBV, Phase III)
bb2121 (CELG, Phase II)
Jakafi (INCY, Phase I)
Neuroendocrine Tumors (NET)
Qarziba (EUSA Pharma, Phase III)
Non-Hodgkin's Lymphoma (NHL)
Lisocabtagene Maraleucel (CELG, Phase II)
Non-Small Cell Lung Cancer (NSCLC)
Opdivo (BMY, Approved)
Keytruda (MRK, Approved)
Keytruda (MRK, Approved)
Dacomitinib (PFE, NDA)
Tecentriq (Roche, Approved)
Tecentriq (Roche, Approved)
Ovarian Cancer
Zeltherva (SLS, Phase I/II)
DCVAC/OvCa (SOTIO Group, Phase II)
Zejula (TSRO, Approved)
Pancreatic Cancer
AM0010 (ARMO, Phase III)
Pigmented Villonodular Synovitis (PVNS)
Pexidartinib (Daiichi Sankyo, Phase III)
Prostate Cancer
ADXS-PSA (ADXS, Phase I/II)
Keytruda (MRK, Phase I/II)
Renal Cell Cancer (RCC)
Keytruda (MRK, Phase III)
Sarcoma
Yondelis (JNJ, Approved)
Selinexor (KPTI, Phase II/III)
Small Cell Lung Cancer (SCLC)
Rova-T (ABBV, Phase III)
Solid Tumors
Epacadostat (INCY, Phase I/II)
NKTR-214 (NTKR, Phase I/II)
JTX-2011 (JNCE, Phase I/II)
LOXO-292 (LOXO, Phase I)
M7824 (MKGAY, Phase I)
Waldenstrom Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL) - NHL
Imbruvica (ABBV, Approved)
Calquence (AZN, Phase II)
List of Biomedtracker ASCO Events
